Short Interest in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Increases By 33.3%

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 10,800 shares, a growth of 33.3% from the March 15th total of 8,100 shares. Based on an average daily trading volume, of 8,200 shares, the short-interest ratio is presently 1.3 days. Currently, 0.1% of the company’s shares are sold short.

CollPlant Biotechnologies Stock Performance

Shares of CLGN opened at $5.24 on Monday. The firm has a market capitalization of $60.00 million, a price-to-earnings ratio of -8.20 and a beta of 0.24. The business’s fifty day moving average price is $5.30 and its two-hundred day moving average price is $5.44. CollPlant Biotechnologies has a 52 week low of $4.22 and a 52 week high of $8.90.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Benjamin F. Edwards & Company Inc. lifted its stake in shares of CollPlant Biotechnologies by 11.3% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 50,150 shares of the company’s stock valued at $320,000 after purchasing an additional 5,100 shares during the period. Villere ST Denis J & Co. LLC lifted its stake in shares of CollPlant Biotechnologies by 20.4% in the 4th quarter. Villere ST Denis J & Co. LLC now owns 361,293 shares of the company’s stock valued at $2,309,000 after purchasing an additional 61,120 shares during the period. Bank of America Corp DE lifted its stake in shares of CollPlant Biotechnologies by 53.9% in the 1st quarter. Bank of America Corp DE now owns 7,389 shares of the company’s stock valued at $52,000 after purchasing an additional 2,589 shares during the period. Credit Suisse AG acquired a new position in shares of CollPlant Biotechnologies in the 4th quarter valued at $51,000. Finally, Jane Street Group LLC acquired a new position in shares of CollPlant Biotechnologies in the 3rd quarter valued at $90,000. 21.69% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a research report on Friday, April 5th.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.